Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Piero Barbanti, MD, PhD, IRCCS San Raffaele Pisana, Rome, Italy, discusses the need for the characterization of patient phenotypes that predict the success of CGRP-directed monoclonal antibody treatment in migraine. Data from clinical studies have deepened our understanding of CGRP-directed monoclonal antibody treatment, with clinical responses being elicited in around 60% of migraine patients. However, predictive markers that indicate whether patients will be non- or super-responders need to be identified. Super responders refer to patients who experience at least a 75% reduction in migraine days. Developing predictive markers for CGRP-directed antibody treatment success will improve the treatment of migraine by making individualized treatment possible. This interview was conducted during the virtual 2021 CONy meeting.